GlassScriptPhysician profile
Sanjay Havaldar
NPI 1881637296
$4,793.92
in general payments reported to CMS, 2019-2025
21 companies · $1,544 in 2025
The $1,544 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $118 · 2021: $196 · 2022: $477 · 2023: $697 · 2024: $1,422 · 2025: $1,544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,662.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,725.23 | 2019-2025 | |
| Gilead Sciences, INC. | $667.33 | 2019-2025 | Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $322.38 | 2022-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $289.84 | 2022-2025 | Tremfya, Stelara |
| Boston Scientific Corporation | $237.29 | 2019-2024 | Exalt Model D |
| Celgene Corporation | $168.15 | 2023-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $152.67 | 2025 | Voquezna |
| Medtronic, INC. | $133.36 | 2023 | Gi Genius |
| Ardelyx, INC. | $123.38 | 2024 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.70 | 2025 | Xifaxan |
| Genzyme Corporation | $110.92 | 2025 | |
| Janssen Scientific Affairs, LLC | $106.43 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $105.22 | 2023 | Zeposia |
| Ethicon US, LLC | $104.63 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $84.48 | 2023 | Dupixent |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $80.46 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $80.34 | 2025 | Iqirvo |
| Pfizer INC. | $78.22 | 2019 | |
| Celltrion USA INC. | $43.46 | 2025 | Vegzelma |
| Allergan, INC. | $34.07 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $24.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Havaldar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.